In November 2023, PolyMedics Innovations (PMI) has taken over the distribution of NexoBrid® and RECELL in selected European countries. PMI will serve customers in Germany, Austria and the Benelux countries with NexoBrid® from the Israeli company Mediwound. NexoBrid® is a non-surgical solution for the removal of necrotic tissue in burns. For RECELL, PMI is the exclusive distributor in Germany, Austria and Switzerland. RECELL is an autologous cell harvesting device used to create a suspension that is applied in spray form and is manufactured by the US company AVITA Medical. With these two products, the German medical technology company PMI completes its own portfolio for the successful treatment of burns and acute wounds.
„Taking burn care to the next level“
“We are delighted that we were able to finalize the sales cooperation agreements with Mediwound and AVITA Medical almost simultaneously. The properties and indications of NexoBrid® and RECELL complement our existing product portfolio. This enables us to take the treatment of burns to the next level,” says Christian Planck, CEO of PolyMedics Innovations.
The owner-managed Kirchheim-based biomedical technology company PolyMedics Innovations offers synthetic skin substitutes for the treatment of burns and acute wounds. The portfolio includes the synthetic epidermal skin substitute SUPRATHEL®, the dermal skin substitute SUPRA SDRM® and the dermis substitute NovoSorb®BTM. SUPRATHEL® has been on the market for almost 20 years and has established itself as the gold standard in burn treatment.
NexoBrid® from Mediwound
NexoBrid® is a non-surgical solution for the removal of necrotic tissue in burns and has been used successfully in burns medicine for many years. NexoBrid® is manufactured by the Israeli company Mediwound. This manufacturer of biopharmaceuticals focuses on enzymatic therapeutics for tissue repair.
Christian Planck, CEO of the Kirchheim-based company PolyMedics Innovations, says: „Nexobrid® represents a tissue sparing, effective debridement option. This selective debridement has become a standard in many burn units around the world. The combination of NexoBrid® with SUPRATHEL® has shown superior outcomes.”
“We are thrilled to establish this collaboration with PMI, bringing NexoBrid® to a broader audience of burn surgeons and improving patients’ lives. PMI’s impressive customer network and capabilities in the DACH and BeNeLux regions will enable a significant step forward in our journey to advance NexoBrid® adoption in Europe as the new standard of care,” said Alicia Torrenova, MediWound’s Vice President of European Operations.
RECELL from AVITA Medical
RECELL is an autologous cell harvesting device used to create a suspension that is applied to the patient on thermal burn wounds and acute wounds and that promotes the healing of skin. The developer of Spray-On Skin™ Cells is the American company AVITA Medical, which is dedicated to the development and commercialization of devices and autologous cell therapies.
PMI-CEO Christian Planck says: “We are excited to finally be able to bring AVITA Medical‘s RECELL back to Germany, Austria and Switzerland. Our customers have been asking for this amazing technology for years. Indeed, it’s a perfect addition to our one-stop-shop technology portfolio.”
“Our partnership with PolyMedics Innovations represents the first step of our strategic global expansion,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “Their proven track record and expertise in the global distribution of innovative wound treatments make them an ideal partner. We look forward to a successful collaboration that will enable us to reach more patients worldwide.”